Literature DB >> 11472419

De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma.

J Y Zhang1, W Zhu, H Imai, K Kiyosawa, E K Chan, E M Tan.   

Abstract

A feature of hepatocellular carcinoma (HCC) is that antecedent liver cirrhosis and chronic hepatitis are common precursor conditions and during transition to malignancy some patients develop autoantibodies which were not present during the preceding chronic liver disease phase. Serum samples from such patients can be used to immunoscreen cDNA expression libraries to identify genes encoding the new autoantigens. We demonstrate here the de novo appearance of antibodies to p62, a cytoplasmic protein which has been shown to bind to a developmentally regulated fetal species of insulin-like growth factor II (IGF-II) mRNA. Another antibody appearing during the transition period was against CENP-F, a cell cycle-related nuclear protein with maximum expression in the G2 and M phases of the cell cycle and previously shown to have a high association with malignancy. In three additional patients in whom serial serum samples were examined, new appearance of anti-p62 was detected in two patients and anti-CENP-F in one patient. This study demonstrates that transition to malignancy can be associated with autoantibody responses to certain cellular proteins which might have some role in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472419      PMCID: PMC1906107          DOI: 10.1046/j.1365-2249.2001.01585.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  53 in total

1.  A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development.

Authors:  J Nielsen; J Christiansen; J Lykke-Andersen; A H Johnsen; U M Wewer; F C Nielsen
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

2.  Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies.

Authors:  U Sahin; O Türeci; Y T Chen; G Seitz; C Villena-Heinsen; L J Old; M Pfreundschuh
Journal:  Int J Cancer       Date:  1998-10-29       Impact factor: 7.396

3.  Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors.

Authors:  J C Antoine; L Absi; J Honnorat; J M Boulesteix; T de Brouker; C Vial; M Butler; P De Camilli; D Michel
Journal:  Arch Neurol       Date:  1999-02

4.  Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer.

Authors:  T Mitsudomi; S Suzuki; Y Yatabe; M Nishio; M Kuwabara; K Gotoh; S Hatooka; M Shinoda; M Suyama; M Ogawa; T Takahashi; Y Ariyoshi; T Takahashi
Journal:  J Natl Cancer Inst       Date:  1998-10-21       Impact factor: 13.506

5.  Clinical evaluation of autoantibodies to p53 protein in patients with chronic liver disease and hepatocellular carcinoma.

Authors:  J Raedle; G Oremek; M Truschnowitsch; M Lorenz; W K Roth; W F Caspary; S Zeuzem
Journal:  Eur J Cancer       Date:  1998-07       Impact factor: 9.162

6.  p53 autoantibodies in the sera, cyst and ascitic fluids of patients with ovarian cancer.

Authors:  M Montenarh; A Harloziñska; J K Bar; S Kartarius; J Günther; P Sedlaczek
Journal:  Int J Oncol       Date:  1998-09       Impact factor: 5.650

7.  The c-myc coding region determinant-binding protein: a member of a family of KH domain RNA-binding proteins.

Authors:  G A Doyle; N A Betz; P F Leeds; A J Fleisig; R D Prokipcak; J Ross
Journal:  Nucleic Acids Res       Date:  1998-11-15       Impact factor: 16.971

8.  Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations.

Authors:  R Ralhan; N Nath; S Agarwal; M Mathur; B Wasylyk; N K Shukla
Journal:  Clin Cancer Res       Date:  1998-09       Impact factor: 12.531

9.  A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma.

Authors:  J Y Zhang; E K Chan; X X Peng; E M Tan
Journal:  J Exp Med       Date:  1999-04-05       Impact factor: 14.307

10.  Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study.

Authors:  P Lenner; F Wiklund; S O Emdin; C Arnerlöv; C Eklund; G Hallmans; H Zentgraf; J Dillner
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

View more
  28 in total

1.  Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis.

Authors:  E M Tan
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

Review 2.  Benign autoimmunity to combat malignancy.

Authors:  H J Stauss
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

3.  Autoantibodies to mitotic apparatus: association with other autoantibodies and their clinical significance.

Authors:  Branka Bonaci-Nikolic; Sladjana Andrejevic; Mirjana Bukilica; Ivana Urosevic; Milos Nikolic
Journal:  J Clin Immunol       Date:  2006-08-29       Impact factor: 8.317

4.  Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma.

Authors:  Kok Sun Looi; Ernesto S Nakayasu; Raquel A de Diaz; Eng M Tan; Igor C Almeida; Jian-Ying Zhang
Journal:  J Proteome Res       Date:  2008-08-02       Impact factor: 4.466

5.  Optimizing peptide epitope-based autoantibody detection in cancer patients.

Authors:  Maize Wang; Shirley H Lomeli; Wilbur A Franklin; Sarah Lee; Allan J Pantuck; Gang Zeng
Journal:  Am J Clin Exp Immunol       Date:  2017-11-01

Review 6.  A systematic review of humoral immune responses against tumor antigens.

Authors:  Miriam Reuschenbach; Magnus von Knebel Doeberitz; Nicolas Wentzensen
Journal:  Cancer Immunol Immunother       Date:  2009-06-28       Impact factor: 6.968

Review 7.  Tumor-associated antigen arrays for the serological diagnosis of cancer.

Authors:  Carlos A Casiano; Melanie Mediavilla-Varela; Eng M Tan
Journal:  Mol Cell Proteomics       Date:  2006-05-29       Impact factor: 5.911

Review 8.  Using immunoproteomics to identify tumor-associated antigens (TAAs) as biomarkers in cancer immunodiagnosis.

Authors:  Qing Zhu; Mei Liu; Liping Dai; Xia Ying; Hua Ye; Yusen Zhou; Suxia Han; Jian-Ying Zhang
Journal:  Autoimmun Rev       Date:  2013-06-24       Impact factor: 9.754

9.  Unclassified renal cell carcinoma: a clinicopathological, comparative genomic hybridization, and whole-genome exon sequencing study.

Authors:  Zhen-Yan Hu; Li-Juan Pang; Yan Qi; Xue-Ling Kang; Jian-Ming Hu; Lianghai Wang; Kun-Peng Liu; Yuan Ren; Mei Cui; Li-Li Song; Hong-An Li; Hong Zou; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

10.  Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis.

Authors:  Zheng Wang; You-Bing Ruan; Yang Guan; Sheng-Hong Liu
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.